ArticleJournal of inflammation research2024
Efficacy of Self-Formulated Ergan Tang on Paroxysmal Atrial Fibrillation in Elderly Patients with Qi-Yin Deficiency: Impact on Inflammatory Marker Levels.
Article in Journal of inflammation research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The aim of this study is to assess the clinical efficacy of the self-formulated Ergan Tang on managing paroxysmal atrial fibrillation (AF) characterized by qi-yin deficiency among elderly patients. Methods: A cohort of 40 elderly patients diagnosed with paroxysmal AF who spontaneously reverted to sinus rhythm were enrolled based on predetermined inclusion and exclusion criteria. These participants were randomly divided into two groups: self-formulated Ergan Tang group and amiodarone group. Following an 8-week treatment regimen, alterations in traditional Chinese medicine (TCM) symptom scores, AF burden, and inflammatory factor levels were monitored in both groups. Furthermore, changes in these parameters were specifically analyzed before and after treatment with the self-formulated Ergan Tang. Results: Baseline clinical and demographic characteristics demonstrated no statistically significant differences between the self-formulated Ergan Tang group and the amiodarone group. Following an 8-week treatment period no significant disparities were observed in TCM symptom scores, AF burden, or AF recurrence rates at the 6-month follow-up between the two groups ( Conclusion: The self-formulated Ergan Tang demonstrates efficacy in alleviating AF burden, reducing inflammatory factor levels, and improving TCM symptom scores among elderly patients with paroxysmal AF characterized by qi-yin deficiency. Notably, its efficacy is comparable to that of amiodarone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.